New Framework for In Vitro BBB Models Optimizes Brain Shuttle Peptide Transport Evaluation

The blood-brain barrier (BBB) presents a formidable obstacle to delivering therapeutics for neurological diseases and brain malignancies. Its specialized tight junctions, low intracellular vesicles, negatively charged glycocalyx, and highly regulated transport mechanisms effectively restrict drug passage into the central nervous system. This inherent protection, while vital for maintaining brain homeostasis, severely limits the efficacy of many promising compounds. Brain shuttle peptides, including antibody fragments and nanocarriers, offer a strategic solution by exploiting endogenous BBB transport pathways like receptor-mediated and adsorptive-mediated transcytosis to enhance brain drug delivery.

This methodological review outlines a comprehensive framework for selecting and applying appropriate in vitro blood-brain barrier (BBB) models to study brain shuttle peptide transport. The authors detail the cellular and methodological considerations crucial for ensuring relevant barrier tightness and cellular composition in chosen models. They explain how to implement rigorous experimental controls to accurately assess key parameters such as transport efficiency, receptor specificity, cytotoxicity, and barrier integrity. The guidance aims to help researchers identify specific transport phenomena and effectively exclude potential experimental artifacts.

The presented framework emphasizes that successful evaluation of brain shuttle peptides hinges on the careful selection and rigorous application of in vitro BBB models. It highlights the importance of matching model characteristics, such as barrier tightness and cellular composition, to the specific transport mechanism being investigated (e.g., receptor-mediated or adsorptive-mediated transcytosis). The paper details how to establish robust experimental controls to differentiate genuine transport from non-specific uptake or artifactual results. Key aspects covered include methods for quantifying transport efficiency, verifying receptor specificity, assessing potential cytotoxicity to BBB cells, and monitoring barrier integrity throughout experiments. > By providing a structured approach, this framework significantly enhances the reliability and interpretability of in vitro studies, enabling researchers to more accurately predict the in vivo performance of brain shuttle peptides and accelerate the development of CNS therapeutics.